Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study investigated the incidence of cardiac dysfunction in patients with advanced or recurrent epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR- tyrosine kinase inhibitors.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| EGFR-TKI | Drug | Erlotinib, dacomitinib, afatinib, and osimertinib, with dose according to NCCN guide line. | ||
| EGFR tyrosine kinase inhibitor | Other | Erlotinib, dacomitinib, afatinib, and osimertinib, with dose according to NCCN guide line |
| Measure | Description | Time Frame |
|---|---|---|
| The incidence of cancer therapy-related cardiac dysfunction after treatment with EGFR tyrosine kinase inhibitors. | Cancer therapy-related cardiac dysfunction was defined as a left ventricular ejection fraction of less than 50% and an absolute reduction in LVEF of more than 10% from baseline. | From enrollment to 2 years after initiating EGFR tyrosine kinase inhibitor treatment. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult patients (≥18 years) with advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations, who are prescribed EGFR tyrosine kinase inhibitors (gefitinib, erlotinib, afatinib, dacomitinib, or osimertinib) as part of routine clinical care at Taichung Veterans General Hospital. All participants will undergo echocardiographic assessment at baseline and follow-up time points according to the study protocol.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Taichung Veterans General Hospital | Taichung | 407 | Taiwan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| D066126 | Cardiotoxicity |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D064420 | Drug-Related Side Effects and Adverse Reactions |
| D064419 | Chemically-Induced Disorders |
| D011832 | Radiation Injuries |
| D014947 | Wounds and Injuries |
Not provided
Not provided
| ID | Term |
|---|---|
| C561722 | EGFR tyrosine kinase inhibitor 324674 |
Not provided
Not provided
Not provided